Monitor for any future conversion of this 13G to a 13D, which would signal an activist shift. The 14.1% stake gives BlackRock significant influence, but the passive filing indicates no current intent to change or influence control.
Price Chart
Executive Summary
BlackRock filed an amended Schedule 13G disclosing a 14.1% passive stake in Arcutis Biotherapeutics as of September 30, 2026, representing 17,751,435 shares of common stock. This is a routine passive ownership update with no change in investment intent, and the filing does not provide prior-period share counts for comparison.
Key Financial Metrics
Key Facts
- BlackRock, Inc. reported beneficial ownership of 17,751,435 shares of Arcutis common stock as of September 30, 2026.
- The stake represents 14.1% of the outstanding common stock.
- BlackRock disclaims beneficial ownership of shares held by its subsidiaries and affiliates, except to the extent of its pecuniary interest.
- The filing is made pursuant to Rule 13d-1(b), confirming passive investment intent.
- One subsidiary, iShares Core S&P Small-Cap ETF, holds more than 5% of the outstanding common stock individually.
- No prior-period share count or percentage is provided in the filing for comparison.
Financial Impact
No financial impact — passive stake disclosure with no change in investment intent.
Risk Factors
- BlackRock could increase or decrease its position without further public disclosure until crossing the next 5% threshold.
- A future conversion to a 13D filing could signal activist intent and create volatility.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0002012383-26-003314 |
| Document: Item_7.txt | 0002012383-26-003314 |
| Document: 0002012383-26-003314-index-headers.html | 0002012383-26-003314 |
| Document: 0002012383-26-003314-index.html | 0002012383-26-003314 |
| Document: 0002012383-26-003314.txt | 0002012383-26-003314 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | Press Release | $32.20 | awaiting T+20 | — | $31.81 (−1.21%) |
Oct 5, 2026 21d ago | SC 13G/A | $25.15 | awaiting T+20 | — | $31.81 (+26.48%) |
Sep 29, 2026 27d ago | Press Release | $26.75 | awaiting T+20 | — | $31.81 (+18.92%) |
Sep 18, 2026 5w ago | Insider Cluster | $25.96 $31.89 | ▲ +22.84% | ▲ +23.75% | $31.81 (+22.53%) |
Sep 17, 2026 5w ago | Insider Cluster | $25.38 $28.82 | ▲ +13.55% | ▲ +13.35% | $31.81 (+25.33%) |
Aug 24, 2026 8w ago | Insider Cluster | $24.86 $26.38 | ▲ +6.11% | ▲ +5.87% | $31.81 (+27.96%) |
Aug 21, 2026 9w ago | Insider Cluster | $24.78 $27.78 | ▲ +12.11% | ▲ +10.81% | $31.81 (+28.37%) |
Aug 19, 2026 9w ago | Insider Cluster | $25.35 $25.38 | ▲ +0.12% | ▲ +0.12% | $31.81 (+25.48%) |
Aug 11, 2026 10w ago | 144 | $26.28 $23.38 | ▼ −11.04% | ▼ −9.14% | $31.81 (+21.04%) |
Aug 5, 2026 11w ago | Insider Cluster | $26.43 $23.66 | ▼ −10.48% | ▼ −11.08% | $31.81 (+20.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers